Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - Kite Pharma, Inc. | kiteex-32106x30x17.htm |
| EX-31.2 - EXHIBIT 31.2 - Kite Pharma, Inc. | kiteex-31206x30x17.htm |
| EX-31.1 - EXHIBIT 31.1 - Kite Pharma, Inc. | kiteex-31106x30x17.htm |
| 10-Q - 10-Q - Kite Pharma, Inc. | kite10q6-30x17.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Kite Pharma, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Paul Jenkinson, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
By: /s/ Paul Jenkinson
Name: Paul Jenkinson
Title: Chief Financial Officer
Date: August 8, 2017
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.